These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
paper_nCov-2019_VS.pdf (220.45 kB)

Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins

submitted on 13.02.2020, 11:45 and posted on 13.02.2020, 13:29 by Alessandro Contini
The infection by the 2019-nCoV coronavirus (COVID-19) is a world-wide emergency.
The crystal structure of a protein essential for virus replication has been filed in the Protein Data
Bank recently. Additionally, homology models of 24 COVID-19 proteins were made available by
the Zhang group. In this paper, we present results deriving from the virtual screening of a database
of more than 3000 FDA approved drugs on two distinct targets. Results showed that some of the
known protease inhibitors currently used in HIV infections might be helpful for the therapy of
COVID-19 also.


Email Address of Submitting Author


Università degli Studi di Milano



ORCID For Submitting Author

Declaration of Conflict of Interest

The author declares no conflict of interest

Version Notes

Version 1.0 reports results of the virtual screening in form of two tables listing the name of the identified compounds. Some consideration are also given on the reliability of results